Rodolakis A, Scambia G, Planchamp F, Acien M, Di Spiezio Sardo A, Farrugia M, Grynberg M, Pakiž M, Pavlakis K, Vermeulen N, Zannoni G, Zapardiel I, Tryde Macklon K L
Facts Views Vis Obgyn. 2023 Mar;15(1):3-23. doi: 10.52054/FVVO.15.1.065. Epub 2023 Feb 6.
The standard surgical treatment of endometrial carcinoma (EC) consisting of total hysterectomy with bilateral salpingo-oophorectomy drastically affects the quality of life of patients and creates a challenge for clinicians. Recent evidence-based guidelines of the European Society of Gynaecological Oncology (ESGO), the European SocieTy for Radiotherapy & Oncology (ESTRO) and the European Society of Pathology (ESP) provide comprehensive guidelines on all relevant issues of diagnosis and treatment in EC in a multidisciplinary setting. While also addressing work-up for fertility preservation treatments and the management and follow-up for fertility preservation, it was considered relevant to further extend the guidance on fertility sparing treatment.
To define recommendations for fertility-sparing treatment of patients with endometrial carcinoma.
ESGO/ESHRE/ESGE nominated an international multidisciplinary development group consisting of practicing clinicians and researchers who have demonstrated leadership and expertise in the care and research of EC (11 experts across Europe). To ensure that the guidelines are evidence-based, the literature published since 2016, identified from a systematic search was reviewed and critically appraised. In the absence of any clear scientific evidence, judgment was based on the professional experience and consensus of the development group. The guidelines are thus based on the best available evidence and expert agreement. Prior to publication, the guidelines were reviewed by 95 independent international practitioners in cancer care delivery and patient representatives.
The multidisciplinary development group formulated 48 recommendations for fertility-sparing treatment of patients with endometrial carcinoma in four sections: patient selection, tumour clinicopathological characteristics, treatment and special issues.
These recommendations provide guidance to professionals caring for women with endometrial carcinoma, including but not limited to professionals in the field of gynaecological oncology, onco-fertility, reproductive surgery, endoscopy, conservative surgery, and histopathology, and will help towards a holistic and multidisciplinary approach for this challenging clinical scenario.
WHAT IS NEW?: A collaboration was set up between the ESGO, ESHRE and ESGE, aiming to develop clinically relevant and evidence-based guidelines focusing on key aspects of fertility-sparing treatment in order to improve the quality of care for women with endometrial carcinoma across Europe and worldwide.
子宫内膜癌(EC)的标准手术治疗包括全子宫切除术加双侧输卵管卵巢切除术,这会严重影响患者的生活质量,给临床医生带来挑战。欧洲妇科肿瘤学会(ESGO)、欧洲放射治疗与肿瘤学会(ESTRO)和欧洲病理学会(ESP)最近发布的循证指南在多学科背景下就子宫内膜癌诊断和治疗的所有相关问题提供了全面指导。虽然该指南也涉及生育力保留治疗的检查以及生育力保留的管理和随访,但进一步扩展关于保留生育功能治疗的指导被认为是有必要的。
为子宫内膜癌患者的保留生育功能治疗制定建议。
ESGO/ESHRE/ESGE提名了一个国际多学科制定小组,成员包括在子宫内膜癌护理和研究方面表现出领导力和专业知识的临床医生和研究人员(来自欧洲各地的11位专家)。为确保指南基于证据,对2016年以来通过系统检索确定的文献进行了回顾和严格评估。在缺乏明确科学证据的情况下,判断基于制定小组的专业经验和共识。因此,这些指南基于现有最佳证据和专家共识。在发布之前,95名癌症护理方面的独立国际从业者和患者代表对指南进行了审查。
多学科制定小组在四个部分为子宫内膜癌患者的保留生育功能治疗制定了48条建议:患者选择、肿瘤临床病理特征、治疗和特殊问题。
这些建议为照顾子宫内膜癌女性患者的专业人员提供指导,包括但不限于妇科肿瘤学、肿瘤生育学、生殖外科、内窥镜检查、保守手术和组织病理学领域的专业人员,并将有助于针对这一具有挑战性的临床情况采取整体和多学科方法。
ESGO、ESHRE和ESGE之间开展了合作,旨在制定关注保留生育功能治疗关键方面的临床相关且基于证据的指南,以提高欧洲乃至全球子宫内膜癌女性患者的护理质量。